Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with costello syndrome

Human Mutation

Volumn 30, Issue 3, 2009, Pages 352-362

  Rosenberger, Georg ^a   Meien, Stefanie ^a   Kutsche, Kerstin ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

AKT; Costello syndrome; CS; ERK; H Ras; HRAS mutation; MAP2K1; MAP2K2; MEK; PKB; Primary skin fibroblasts; RAS MAPK pathway; Sustained PI3K signaling

Indexed keywords

EPIDERMAL GROWTH FACTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COSTELLO SYNDROME; DISEASE ASSOCIATION; GENE MUTATION; HARVEY SARCOMA ONCOVIRUS; HUMAN; IMMUNOBLOTTING; NUCLEOTIDE SEQUENCE; ONCOGENE; PHOSPHORYLATION; PRIORITY JOURNAL; SKIN FIBROBLAST; STIMULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ABNORMALITIES, MULTIPLE; CELLS, CULTURED; CHROMONES; CRANIOFACIAL ABNORMALITIES; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FAILURE TO THRIVE; FIBROBLASTS; GUANOSINE TRIPHOSPHATE; HUMANS; IMMUNOBLOTTING; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MENTAL RETARDATION; MORPHOLINES; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION; SKIN; SKIN ABNORMALITIES; SYNDROME;

EID: 61649121052     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.20855     Document Type: Article

References (74)

1. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y. 2005. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37:1038-1040.
2. Bos JL. 1989. Ras oncogenes in human cancer: a review. Cancer Res 49:4682-4689.
3. Buday L, Downward J. 1993. Epidermal growth factor regulates the exchange rate of guanine nucleotides on p21ras in fibroblasts. Mol Cell Biol 13:1903-1910.
4. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD. 2000. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19:6341-6350.
5. Cantley LC. 2002. The phosphoinositide 3-kinase pathway. Science 296:1655-1657.
6. Caron RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, Hawkins W, Sasazuki T, Shirasawa S, Kozikowski AP, Dennis PA, Hagan MP, Grant S, Dent P. 2005. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 4:257-270.
7. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr. 2002. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99:12333-12338.
8. de Rooij J, Bos JL. 1997. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 14:623-625.
9. Denayer E, Parret A, Chmara M, Schubbert S, Vogels A, Devriendt K, Frijns JP, Rybin V, de Ravel TJ, Shannon K, Cools J, Scheffzek K, Legius E. 2007. Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 29:232-239.
10. Der CJ, Finkel T, Cooper GM. 1986. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 44:167-176.
11. Ellis CA, Clark G. 2000. The importance of being K-Ras. Cell Signal 12:425-434.
12. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA. 2006. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A 140:8-16.
13. Farnsworth CL, Feig LA. 1991. Dominant inhibitory mutations in the Mg(2+)-binding site of RasH prevent its activation by GTP. Mol Cell Biol 11:4822-4829.
14. Fayard E, Tintignac LA, Baudry A, Hemmings BA. 2005. Protein kinase B/Akt at a glance. J Cell Sci 118(Pt 24):5675-5678.
15. Feig LA. 1993. The many roads that lead to Ras. Science 260:767-768.
16. Feng GS, Hui CC, Pawson T. 1993. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science 259:1607-1611.
17. Fragale A, Tartaglia M, Wu J, Gelb BD. 2004. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum Mutat 23:267-277.
18. Franken SM, Scheidig AJ, Krengel U, Rensland H, Lautwein A, Geyer M, Scheffzek K, Goody RS, Kalbitzer HR, Pai EF, Wittinghofer A. 1993. Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-ras. Biochemistry 32:8411-8420.
19. Frech M, Darden TA, Pedersen LG, Foley CK, Charifson PS, Anderson MW, Wittinghofer A. 1994. Role of glutamine-61 in the hydrolysis of GTP by p21H-ras: an experimental and theoretical study. Biochemistry 33:3237-3244.
20. Gibbs JB, Sigal IS, Poe M, Scolnick EM. 1984. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci USA 81:5704-5708.
21. Giehl K. 2005. Oncogenic Ras in tumour progression and metastasis. Biol Chem 386:193-205.
22. Giehl K, Skripczynski B, Mansard A, Menke A, Gierschik P. 2000. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. Oncogene 19:2930-2942.
23. Gopalbhai K, Meloche S. 1998. Repression of mitogen-activated protein kinases ERK1/ERK2 activity by a protein tyrosine phosphatase in rat fibroblasts transformed by upstream oncoproteins. J Cell Physiol 174:35-47.
24. Gripp KW, Scott CI, Jr, Nicholson L, McDonald-McGinn DM, Ozeran JD, Jones MC, Lin AE, Zackai EH. 2002. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet 108:80-87.
25. Gripp KW. 2005. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 137:72-77.
26. Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI, Jr, Doyle D, Aoki Y, Matsubara Y, Zackai EH, Lapunzina P, Gonzalez-Meneses A, Holbrook J, Agresta CA, Gonzalez IL, Sol-Church K. 2006. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 140:1-7.
27. Guo Z, Ahmadian MR, Goody RS. 2005. Guanine nucleotide exchange factors operate by a simple allosteric competitive mechanism. Biochemistry 44:15423-15429.
28. Harris IS, Zhang S, Treskov I, Kovacs A, Weinheimer C, Muslin AJ. 2004. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110:718-723.
29. Hattori S, Fukuda M, Yamashita T, Nakamura S, Gotoh Y, Nishida E. 1992. Activation of mitogen-activated protein kinase and its activator by ras in intact cells and in a cell-free system. J Biol Chem 267:20346-20351.
30. Hennekam RC. 2003. Costello syndrome: an overview. Am J Med Genet C Semin Med Genet 117:42-48.
31. Hinek A, Smith AC, Cutiongco EM, Callahan JW, Gripp KW, Weksberg R. 2000. Decreased elastin deposition and high proliferation of fibroblasts from Costello syndrome are related to functional deficiency in the 67-kD elastin-binding protein. Am J Hum Genet 66:859-872.
32. Hinek A, Teitell MA, Schoyer L, Allen W, Gripp KW, Hamilton R, Weksberg R, Kluppel M, Lin AE. 2005. Myocardial storage of chondroitin sulfate-containing moieties in Costello syndrome patients with severe hypertrophic cardiomyopathy. Am J Med Genet A 133:1-12.
33. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. 1995. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 270:23173-23178.
34. Iida M, Towatari M, Nakao A, Iida H, Kiyoi H, Nakano Y, Tanimoto M, Saito H, Naoe T. 1999. Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation. Leukemia 13:585-589.
35. Kappler R, Calzada-Wack J, Schnitzbauer U, Koleva M, Herwig A, Piontek G, Graedler F, Adamski J, Heinzmann U, Schlegel J, Hemmerlein B, Quintanilla-Martinez L, Hahn H. 2003. Molecular characterization of Patched-associated rhabdomyosarcoma. J Pathol 200:348-356.
36. Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden OB, O'Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cave H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G. 2006. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet 43:401-405.
37. Krengel U, Schlichting L, Scherer A, Schumann R, Frech M, John J, Kabsch W, Pai EF, Wittinghofer A. 1990. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules. Cell 62:539-548.
38. Li W, Zhu T, Guan KL. 2004. Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK. J Biol Chem 279:37398-37406.
39. Lin AE, Grossfeld PD, Hamilton RM, Smoot L, Gripp KW, Proud V, Weksberg R, Wheeler P, Picker J, Irons M, Zackai E, Marino B, Scott CI Jr, Nicholson L. 2002. Further delineation of cardiac abnormalities in Costello syndrome. Am J Med Genet 111:115-129.
40. Luo W, Sharif M. 1999. Stable expression of activated Ki-Ras does not constitutively activate the mitogen-activated protein kinase pathway but attenuates epidermal growth factor receptor activation in human astrocytoma cells. Int J Oncol 14:53-62.
41. Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
42. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, Liao R, Rosenzweig A. 2002. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277:22896-22901.
43. McGrath JP, Capon DJ, Goeddel DV, Levinson AD. 1984. Comparative biochemical properties of normal and activated human ras p21 protein. Nature 310:644-649.
44. Mittal R, Ahmadian MR, Goody RS, Wittinghofer A. 1996. Formation of a transition-state analog of the Ras GTPase reaction by Ras-GDP, tetrafluoroaluminate, and GTPase-activating proteins. Science 273:115-117.
45. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y. 2006. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38:294-296.
46. Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, Bos JM, Ommen SR, Esposito G, Lepri F, Faul C, Mundel P, Lopez Siguero JP, Tenconi R, Selicorni A, Rossi C, Mazzanti L, Torrente I, Marino B, Digilio MC, Zampino G, Ackerman MJ, Dallapiccola B, Tartaglia M, Gelb BD. 2007. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet 39:1007-1012.
47. Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, Kamisago M, Momma K, Katayama H, Nakagawa M, Fujiwara Y, Matsushima M, Mizuno K, Tokuyama M, Hirota H, Muneuchi J, Higashinakagawa T, Matsuoka R. 2007. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet 39:1013-1017.
48. Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, Young T, Neri G. 2006. The cardiofaciocutaneous syndrome. J Med Genet 43:833-842.
49. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J. 1994. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532.
50. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J. 1997. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457-467.
51. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. 2006. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311:1287-1290.
52. Satoh T, Endo M, Nakafuku M, Akiyama T, Yamamoto T, Kaziro Y. 1990. Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. Proc Natl Acad Sci USA 87:7926-7929.
53. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A. 1997. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277:333-338.
54. Scheffzek K, Ahmadian MR. 2005. GTPase activating proteins: structural and functional insights 18 years after discovery. Cell Mol Life Sci 62:3014-3038.
55. Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in developmental disorder and cancer. Nat Rev Cancer 7:295-308.
56. Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, Heller R, Horn D, Hübner CA, Korenke GC, König R, Kress W, Krüger G, Meinecke P, Mücke J, Plecko B, Rossier E, Schinzel A, Schulze A, Seemanova E, Seidel H, Spranger S, Tuysuz B, Uhrig S, Wieczorek D, Kutsche K, Zenker M. 2008. Mutation and phenotypic spectrum in patients with cardio-faciocutaneous (CFC) and Costello syndrome. Clin Genet 73:62-70.
57. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD. 1984. Biological properties of human c-Ha-ras1 genes mutated at codon 12. Nature 312:71-75.
58. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J, Cantley LC, Izumo S. 2000. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19:2537-2548.
59. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S. 2002. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22:2799-2809.
60. Skinner J, Bounacer A, Bond JA, Haughton MF, deMicco C, Wynford-Thomas D. 2004. Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis. Oncogene 23:5994-5999.
61. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, Sausville EA, Sawai ET, Gutkind JS. 2004. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA 101:4821-4826.
62. Sweet RW, Yokoyama S, Kamata T, Feramisco JR, Rosenberg M, Gross M. 1984. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311:273-275.
63. Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I, Hamada K, Ueda T, Naka N, Kudawara I, Aozasa K. 2006. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res 12:3070-3077.
64. van der Burgt I, Kupsky W, Stassou S, Nadroo A, Barroso C, Diem A, Kratz CP, Dvorsky R, Ahmadian MR, Zenker M. 2007. Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. J Med Genet 44:459-462.
65. van Steensel MA, Vreeburg M, Peels C, van Ravenswaaij-Arts CM, Bijlsma E, Schrander-Stumpel CT, van Geel M. 2006. Recurring HRAS mutation G12S in Dutch patients with Costello syndrome. Exp Dermatol 15:731-734.
66. Vetter IR, Wittinghofer A. 2001. The guanine nucleotide-binding switch in three dimensions. Science 294:1299-1304.
67. Villalonga P, Lopez-Alcala C, Bosch M, Chiloeches A, Rocamora N, Gil J, Marais R, Marshall CJ, Bachs O, Agell N. 2001. Calmodulin binds to K-Ras, but not to H-or N-Ras, and modulates its downstream signaling. Mol Cell Biol 21:7345-7354.
68. Vlahos CJ, Matter WF, Hui KY, Brown RF. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 269:5241-5248.
69. Wan X, Helman LJ. 2003. Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II- overexpressing rhabdomyosarcomas cells. Oncogene 22:8205-8211.
70. Wellbrock C, Karasarides M, Marais R. 2004. The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875-885.
71. Yamaguchi O, Watanabe T, Nishida K, Kashiwase K, Higuchi Y, Takeda T, Hikoso S, Hirotani S, Asahi M, Taniike M, Nakai A, Tsujimoto I, Matsumura Y, Miyazaki J, Chien KR, Matsuzawa A, Sadamitsu C, Ichijo H, Baccarini M, Hori M, Otsu K. 2004. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 114:937-943.
72. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. 1998. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 273:24052-24056.
73. Yip-Schneider MT, Lin A, Barnard D, Sweeney CJ, Marshall MS. 1999. Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. Int J Oncol 15:271-279.
74. Zampino G, Pantaleoni F, Carta C, Cobellis G, Vasta I, Neri C, Pogna EA, De Feo E, Delogu A, Sarkozy A, Atzeri F, Selicorni A, Rauen KA, Cytrynbaum CS, Weksberg R, Dallapiccola B, Ballabio A, Gelb BD, Neri G, Tartaglia M. 2007. Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 28:265-272.